Abbott director granted 2,286 restricted stock units

Kumbier Michelle reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kumbier Michelle reported acquisition or exercise transactions in this Form 4 filing.

Abbott Laboratories director Michelle Kumbier received a grant of 2,286 restricted stock units. The award was made in the form of common shares without par value at no purchase price and is part of Abbott’s 2026 Incentive Stock Program.

The restricted stock units will be paid in Abbott common shares on a one-to-one basis upon the earlier of Kumbier’s separation from service, death, or a change in control as defined in the program. Following this grant, she directly holds 18,000 Abbott common shares.

Insider Trade Summary

Grant/Award: 2,286 shares

Grant/Award 1 txn

Insider Kumbier Michelle

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common shares without par value	2,286	$0.00	$0.00

Holdings After Transaction: Common shares without par value — 18,000 shares (Direct)

Footnotes (1)

1. F1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Key Figures

Restricted stock units granted: 2,286 shares Price per share for grant: $0.0000 per share Shares held after transaction: 18,000 shares +1 more

4 metrics

Restricted stock units granted 2,286 shares Grant to director Michelle Kumbier on reported transaction date

Price per share for grant $0.0000 per share Compensation grant, not an open-market purchase

Shares held after transaction 18,000 shares Total Abbott common shares directly owned by Michelle Kumbier after grant

Conversion ratio 1:1 into common shares Restricted stock units paid in Abbott common shares under 2026 Incentive Stock Program

Key Terms

Restricted stock unit award, 2026 Incentive Stock Program, separation from service, change in control

4 terms

Restricted stock unit award financial

"Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

2026 Incentive Stock Program financial

"granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program")"

separation from service financial

"paid ... on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control"

change in control financial

"death, or the occurrence of a change in control (as defined in the Program)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Abbott Laboratories (ABT) report for Michelle Kumbier?

Abbott Laboratories reported that director Michelle Kumbier received a grant of 2,286 restricted stock units. These units were awarded at no purchase price and will settle in Abbott common shares on a one-to-one basis upon separation from service, death, or a qualifying change in control.

How many Abbott (ABT) shares does Michelle Kumbier hold after this Form 4 transaction?

After the reported grant, Michelle Kumbier holds 18,000 Abbott common shares directly. This total reflects the addition of 2,286 restricted stock units awarded under the company’s 2026 Incentive Stock Program, which will convert into common shares when specified triggering events occur.

Was Michelle Kumbier’s Abbott (ABT) stock award a market purchase or a compensation grant?

The transaction was a compensation-related grant, not a market purchase. Michelle Kumbier received 2,286 restricted stock units at a price of $0.0000 per share under Abbott’s 2026 Incentive Stock Program, reflecting an equity award rather than an open-market buy order.

When will Michelle Kumbier’s Abbott (ABT) restricted stock units be settled into shares?

The restricted stock unit award will be paid in Abbott common shares on a one-to-one basis at the earlier of Kumbier’s separation from service, her death, or a change in control, as defined in Abbott’s 2026 Incentive Stock Program governing the grant’s terms.

What program governs Michelle Kumbier’s new Abbott (ABT) stock unit grant?

The grant is governed by the Abbott Laboratories 2026 Incentive Stock Program. Under this program, Kumbier’s 2,286 restricted stock units convert into Abbott common shares upon specific events such as separation from service, death, or a qualifying change in control set out in the plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 06:45 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumbier Michelle

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	04/24/2026		A		2,286(1)	A	$0	18,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

	/s/ Michelle A. Kumbier by Jessica H. Paik , Attorney-in-Fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)